

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/837,998	04/19/2001	Bertram Jacobs	A33781 - 072448.0308	8865
75	590 04/12/2002			
BAKER BOTTS L.L.P. 44TH FLOOR 30 ROCKEFELLER PLAZA			EXAMINER	
			GUZO, DAVID	
NEW YORK, NY 10112-4498			ART UNIT	PAPER NUMBER
			1636 DATE MAILED: 04/12/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		09/837,998	JACOBS ET AL.			
		Examiner	Art Unit			
		David Guzo	1636			
Period fo	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
THE - Exte after - If the - If NO - Failu - Any I	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period we re to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ad patent term adjustment. See 37 CFR 1.704(b).	6(a). In no event, however, may a reply be tim within the statutory minimum of thirty (30) days ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
1)[Responsive to communication(s) filed on 12 F	ebruary 2002 .				
2a)⊠		s action is non-final.				
3)	· <u> </u>					
Dispositi	on of Claims					
4)⊠	☑ Claim(s) <u>1-9</u> is/are pending in the application.					
	4a) Of the above claim(s) <u>7</u> is/are withdrawn from consideration.					
5)	Claim(s) is/are allowed.					
6)⊠	6)⊠ Claim(s) <u>1,2,4 and 5</u> is/are rejected.					
7)🖂	7)⊠ Claim(s) <u>3,6</u> is/are objected to.					
8) Claim(s) are subject to restriction and/or election requirement. Application Papers						
9) The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12)☐ The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
	1. Certified copies of the priority documents have been received.					
	2. Certified copies of the priority documents have been received in Application No					
* 8	 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received. 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
2) 🔲 Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal P	(PTO-413) Paper No(s) Patent Application (PTO-)52)			
S Patent and Tr	ademark Office		7			

Art Unit: 1636

DETAILED ACTION

Newly submitted claim 7 is directed to an invention that is independent or distinct from the invention originally claimed for the following reasons:

Inventions I (Claims 1-6) and II (Claim 7) are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product of Group I can be used to express genes of interest in cells in culture.

Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claim 7 is withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 1, 2, 4 and 5 are rejected under 35 U.S.C. 102(a) as being anticipated by Brandt et al. (Cited by applicants).

Both applicants and Brandt et al. (J. Virol., Jan. 2001, Vol. 75, No. 2, pp. 850-856, see whole article, particularly the Abstract, Fig. 1 and pp. 853-854) recite an

Application/Control Number: 09/837,998

Art Unit: 1636

expression vector (which can be in a carrier) comprising a vaccinia virus with **reduced** - **pathogenicity** in an animal host which comprises a deletion in the E3L gene (both Brandt et al. and applicants recite deletions in the carboxy-terminal portion of the protein) and wherein the vector further comprises exogenous DNA (which can encode an antigen such as β-galactosidase) operably linked to regulatory elements that control expression of said exogenous DNA. Brandt et al. also recites a method for making a recombinant gene product comprising subjecting said vaccinia expression vector to conditions whereby the exogenous gene product is expressed. Brandt et al. therefore teaches the claimed invention.

No Claims are allowed.

Claims 3 and 6 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not

Application/Control Number: 09/837,998

Art Unit: 1636

mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Guzo whose telephone number is (703) 308-1906. The examiner can normally be reached on Monday-Thursday from 8:00 AM to 5:30 PM. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Irem Yucel, can be reached on (703) 305-1998. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding or relating to attachments to this Office Action should be directed to Patent Analyst Zeta Adams whose telephone number is (703) 305-3291.

David Guzo April 9, 2002

DAVID GUZO